Azitra, Inc. (NYSEAMERICAN:AZTR – Free Report) – Equities research analysts at Zacks Research lifted their FY2026 earnings per share estimates for shares of Azitra in a note issued to investors on Wednesday, March 4th. Zacks Research analyst J. Vandermosten now expects that the company will post earnings of ($0.71) per share for the year, up from their previous estimate of ($0.88). The consensus estimate for Azitra’s current full-year earnings is ($2.78) per share. Zacks Research also issued estimates for Azitra’s FY2027 earnings at ($0.55) EPS.
Azitra Trading Down 7.1%
AZTR opened at $0.18 on Friday. The business’s 50-day moving average is $0.24 and its two-hundred day moving average is $0.47. Azitra has a 1 year low of $0.15 and a 1 year high of $2.66.
Azitra Company Profile
Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.
The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.
Featured Stories
- Five stocks we like better than Azitra
- Silver Is the New Oil—And the World’s Running Dry
- BNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align
- 1,500 Banks Just Handed the Fed Your Bank Account
- Silver paying 20% dividend. Plus 68% share gains
- [How To] Invest Pre-IPO In SpaceX With $100!
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
